Dr. Stuart Hannah
Founder at Microplate Dx, Royal Society of Edinburgh Enterprise Fellow
Dr Stuart Hannah is a Royal Society of Edinburgh Enterprise Fellow and CEO of University of Stratclyde spinout company, Microplate Dx. He has an undergraduate and PhD in Electronic & Electrical Engineering from the University of Stratclyde, and his interests include biosensors, antimicrobial resistance and commercialisation.
Microplate Dx specialises in developing novel in vitro diagnostic tests to tackle the major global threat to public health of antimicrobial resistance (AMR). Microplate Dx’s proprietary technology enables clinicians, at the point of care, to rapidly select the best choice of antibiotic to treat a particular infection in <1 hour, 8-10x quicker than the closest competition. Rapid antibiotic selection prevents AMR, and saves lives (e.g. sepsis). The first product under development is for difficult-to-treat urinary tract infections (UTIs) (1 in 3 women will suffer from a UTI by age of 24, and 1 in 4 sepsis presentations are a result of a poorly-treated UTI).